Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.

This is a pre-specified post-hoc metabolomic and lipidomic analysis drawn from two randomized, placebo-controlled phase 2 trials, so the underlying design is strong though the analysis is exploratory. Higher retatrutide doses were associated with biomarker shifts linked to fatty acid oxidation and lower insulin resistance. Findings are mechanistic and hypothesis-supporting rather than clinical endpoints.